Welcome to our dedicated page for Sartorius Pfd news (Ticker: SUVPF), a resource for investors and traders seeking the latest updates and insights on Sartorius Pfd stock.
SARTORIUS AG PFD W/O (SUVPF) relates to preferred shares of Sartorius AG, a life science group that regularly publishes news about its activities in biopharmaceutical research and manufacturing. The company’s communications highlight developments in its Lab Products & Services and Bioprocess Solutions divisions, as well as updates on capacity expansions, acquisitions, and sustainability initiatives that affect its global operations.
News about Sartorius often covers bioprocessing technologies, including single-use solutions for manufacturing biotech drugs, vaccines, and cell and gene therapies. Company releases describe investments in new production sites and hubs, such as facilities in South Korea, North America, and China, which are intended to bring manufacturing and service capabilities closer to key biopharma markets. These updates provide context on how Sartorius is expanding its footprint and responding to demand in the life science and biopharmaceutical sectors.
Another recurring theme in Sartorius news is portfolio development through acquisitions and product innovation. The company reports on acquisitions of complementary businesses, such as cell culture media specialists, and on enhancements to its laboratory and bioprocess offerings. Recent communications also emphasize sustainability-related news, including the use of ISCC Plus-certified renewable raw materials in selected products to reduce reliance on fossil-based plastics in bioprocessing applications.
Investors and observers following SUVPF-related news can expect updates on Sartorius’ financial performance, divisional growth, capacity expansion projects, and initiatives in areas like sustainability and bioanalytics. This news flow offers insight into how the company positions itself within the life science and biopharmaceutical landscape and how its strategic decisions may influence its long-term development.
Sartorius has expanded its Application and Service Hub in Zhangjiang Science City, Shanghai, to enhance support for the growing biopharmaceutical market in China. Covering over 3,000 square meters, the facility includes a new Application Center 3.0 and Confidence® Validation Services Laboratory 2.0. This investment, aimed at meeting local demand, introduces innovations in drug discovery and process development. Key features include a doubling of validation capacity and the introduction of new testing capabilities. Sartorius plans to continue expanding its local presence and services, employing over 700 staff in China.
Sartorius, through Sartorius Stedim Biotech, has acquired cell culture specialist Xell AG for around 50 million euros, plus earn-out components based on revenue targets from 2022 to 2025. Xell AG, headquartered in Bielefeld, Germany, focuses on media and feed supplements for cell cultures, particularly in gene therapeutics and vaccines, with an expected revenue of 5 million euros in 2021. The acquisition aims to enhance Sartorius's media offerings and accelerate production network expansion in a rapidly growing sector.
Sartorius reported strong growth in the first half of 2021, with sales revenue increasing by 60.1% to approximately 1,629 million euros. Order intake surged by 82.4% to 2,179 million euros. The company benefited from high demand for biopharmaceutical technologies, driven partly by the pandemic. Underlying EBITDA rose 89.2% to 555 million euros, resulting in a margin of 34.1%. Sartorius raised its full-year sales growth forecast to around 45% and anticipates continued strong performance across all divisions.
Sartorius, based in Göttingen, Germany, projects strong growth in the first half of 2021, estimating revenue growth of approximately 60% in constant currencies. They anticipate an underlying EBITDA margin slightly above 34%. The Bioprocess Solutions Division expects a 63% revenue increase, while the Lab Products & Services Division is estimated to grow by 52%. Following this performance, Sartorius has raised its full-year sales growth forecast to around 45%. The company will release detailed half-year figures on July 21, 2021.
Sartorius has acquired a 51% stake in CellGenix GmbH for approximately 100 million euros, enhancing its capabilities in cell and gene therapy production. This acquisition, with plans to acquire the remaining shares by 2026, positions Sartorius to leverage CellGenix's expertise and reputation in the biopharma sector. CellGenix generated over 20 million euros in sales in 2020, boasting a strong EBITDA margin. Sartorius aims to expand the Freiburg site as a center of excellence for quality-critical raw materials, aiming to accelerate drug development timelines.
Sartorius released its annual report, confirming a 30.2% surge in group sales revenue to nearly 2,336 million euros for 2020. Order intake increased 49.0%, reaching 2,836 million euros, driven largely by pandemic-related demand. The underlying EBITDA rose 39.6% to 692 million euros, with a margin climbing to 29.6%. The company expects continued strong growth in 2021, projecting sales revenue to increase by 19% to 25%. Sartorius aims to achieve 5 billion euros in sales by 2025, with significant expansions in production capabilities.